Cell Death and Disease · 2020 · 41 citations · 33 references
Life SciencesBiochemistryPharmacologyCellular MetabolismMetabolic RegulationMetabolismAdipose TissueCarbohydrate MetabolismEnergy BalanceHepatic MetabolismLipid MetabolismMetabolic SignalingAdipocyte BiologyAdipocyte MetabolismForkhead Box Protein O1 RegulationHepatic Metabolic RegulationLiver Metabolism RegulationMetabolic Enzyme InhibitionTranscriptional Control Of Lipogenic GenesWhite Adipose Tissue Biology
The histone acetyltransferases CREB-binding protein (CBP) and its paralogue p300 are transcriptional coactivators which are essential for a multitude of signaling pathways and energy homeostasis. However, the role of CBP/p300 HAT domain in regulating energy balance is still unclear. Here, C57BL/6 mice fed with either normal chow diet (NCD) or high-fat diet (HFD) were administrated with A-485, a recently reported selective inhibitor of CBP/p300 HAT activity for 1 week and the metabolic change was analyzed. The white adipose tissue (WAT) weight and adipocyte size were reduced in A-485-administrated mice, with decreased expressions of lipogenic genes and transcriptional factors. In the liver of A-485-treated mice, the lipid content and lipogenic gene expressions were lowered while the binding of forkhead box O1 (FOXO1) to glucose-6-phosphatase (G6Pc) promoter was reduced, leading to decreased expression of G6Pc. In primary mouse hepatocytes, A-485 abolished cAMP-elicited mRNA expressions of key gluconeogenic enzymes and promoted FOXO1 protein degradation via increasing its ubiquitination. Thus, A-485 inhibits lipogenesis in WAT and liver as well as decreases hepatic glucose production via preventing FOXO1 acetylation, leading to its protein degradation through a proteasome-dependent pathway. The specific inhibition of CBP/p300 HAT will provide a novel therapeutic approach for metabolic diseases.
33
Regulation of Cellular Metabolism by Protein Lysine Acetylation
Shimin Zhao, Wei Xu, Wenqing Jiang et al. · Science · 2010 · 1.9K citations
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Jill C. Milne, Philip Lambert, Simon Schenk et al. · Nature · 2007 · 1.7K citations · Full text
The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism
Seung‐Hoi Koo, Lawrence Flechner, Ling Qi et al. · Nature · 2005 · 975 citations